Neurosense Therapeutics Ltd. (NRSN) Price & Analysis

Compare

158 Followers

NRSN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.64 - $2.60

Previous CloseN/A

Volume34.16K

Average Volume (3M)330.91K

Market Cap

$32.97M

Enterprise Value$24.53M

Total Cash (Recent Filing)$344.00K

Total Debt (Recent Filing)$19.00K

Price to Earnings (P/E)―

Beta1.61

Next Earnings

Nov 26, 2025

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.22

Shares Outstanding24,602,406

10 Day Avg. Volume488,240

30 Day Avg. Volume330,914

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.74

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.85

Forecast

1Y Price Target

$14.00

Price Target Upside1011.11% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Research And DevelopmentNeuroSense is continuing to progress the development of PrimeC for treating amyotrophic lateral sclerosis (ALS) and has completed the scale-up of its manufacturing process to commercial scale.

Bears Say

Financial ConstraintsNRSN finished with $3.4M in cash and equivalents, which is not sufficient to fund the Phase 3 trial.

Funding ChallengesCapital constraints, including 'baby shelf' limitations, make it difficult to raise sufficient capital to fully finance the Phase 3 trial.

Regulatory ChallengesShares are downgraded to Hold due to the unlikelihood of pursuing an Accelerated Approval pathway in the U.S. for PrimeC.

Neurosense Therapeutics Ltd. News

NeuroSense Therapeutics Advances ALS Treatment with Phase 3 Trial Plans

Neurosense Therapeutics Ltd. ( ($NRSN) ) just unveiled an announcement. On August 1, 2025, NeuroSense Therapeutics provided a...

7d ago

NRSN

NeuroSense Therapeutics Releases Q2 2025 Corporate Update

Neurosense Therapeutics Ltd. ( ($NRSN) ) has provided an update. On July 10, 2025, NeuroSense Therapeutics Ltd. released...

29d ago

NRSN

NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval

An announcement from Neurosense Therapeutics Ltd. ( ($NRSN) ) is now available. NeuroSense Therapeutics Ltd. recently completed a...

1M ago

NRSN

Target downgraded, Wayfair upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

NeuroSense initiated with a Buy at D. Boral Capital

D. Boral Capital analyst Jason Kolbert initiated coverage of NeuroSense (NRSN) with a Buy rating and $14 price...

3M ago

NRSN

NeuroSense Completes PrimeC Manufacturing Scale-Up for Canadian Launch

Neurosense Therapeutics Ltd. ( ($NRSN) ) just unveiled an announcement. On May 7, 2025, NeuroSense Therapeutics Ltd. announced...

3M ago

NRSN

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership

Neurosense Therapeutics Ltd. ( ($NRSN) ) just unveiled an update. NeuroSense Therapeutics Ltd. recently issued a letter to...

4M ago

NRSN

NeuroSense Therapeutics Reports 2024 Financial Results

Neurosense Therapeutics Ltd. ( ($NRSN) ) has released its Q4 earnings. Here is a breakdown of the information...

4M ago

NRSN

NeuroSense Therapeutics Reports 2024 Financial Results and Advances ALS Treatment

Neurosense Therapeutics Ltd. ( ($NRSN) ) has provided an announcement. On April 7, 2025, NeuroSense Therapeutics announced its...

4M ago

NRSN

NeuroSense Updates on Pharmaceutical Partnership Discussions

Neurosense Therapeutics Ltd. ( ($NRSN) ) has provided an update. NeuroSense Therapeutics Ltd. announced an update regarding its...

4M ago

NRSN

NeuroSense Advances PrimeC Commercialization in Canada

The latest announcement is out from Neurosense Therapeutics Ltd. ( ($NRSN) ). NeuroSense Therapeutics Ltd. announced progress towards...

5M ago

NRSN

NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment

Neurosense Therapeutics Ltd. ( ($NRSN) ) has provided an announcement. NeuroSense Therapeutics Ltd. has reported additional positive findings...

6M ago

NRSN

NeuroSense regains Nasdaq compliance

NeuroSense (NRSN) Therapeutics announced that the company received formal written notice from The Nasdaq Stock Market that the...

7M ago

NRSN

NeuroSense files to sell 5.28M ordinary shares for holders

16:51 EST NeuroSense (NRSN) files to sell 5.28M ordinary shares for holders Published first on TheFly – the...

7M ago

NRSN

NRSN FAQ

What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?

Neurosense Therapeutics Ltd. lowest stock price was $0.64 and its highest was $2.60 in the past 12 months.

What is Neurosense Therapeutics Ltd.’s market cap?

Neurosense Therapeutics Ltd.’s market cap is $32.97M.

When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?

Neurosense Therapeutics Ltd.’s upcoming earnings report date is Nov 26, 2025 which is in 110 days.

How were Neurosense Therapeutics Ltd.’s earnings last quarter?

Neurosense Therapeutics Ltd. released its earnings results on Aug 01, 2025. The company reported -$0.223 earnings per share for the quarter, the consensus estimate of -$0.223 by $0.

Is Neurosense Therapeutics Ltd. overvalued?

According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Neurosense Therapeutics Ltd. pay dividends?

Neurosense Therapeutics Ltd. does not currently pay dividends.

What is Neurosense Therapeutics Ltd.’s EPS estimate?

Neurosense Therapeutics Ltd.’s EPS estimate is -0.06.

How many shares outstanding does Neurosense Therapeutics Ltd. have?

Neurosense Therapeutics Ltd. has 24,602,406 shares outstanding.

What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?

Neurosense Therapeutics Ltd. reported an EPS of -$0.223 in its last earnings report, expectations of -$0.223. Following the earnings report the stock price went down -40%.

Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?

Currently, no hedge funds are holding shares in NRSN

Neurosense Therapeutics Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-2880.11%

Trailing 12-Months

Asset Growth

44.05%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neurosense Therapeutics Ltd.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Neurosense Therapeutics Ltd. (NRSN) Earnings & Revenues

Historic Earnings Reports

NRSN Stock 12 Month Forecast

Average Price Target

$14.00

▲(1011.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2023","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.08,2.073846153846154,3.0676923076923077,4.061538461538461,5.055384615384615,6.049230769230769,7.043076923076923,8.036923076923078,9.03076923076923,10.024615384615384,11.018461538461539,12.012307692307692,13.006153846153845,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.08,2.073846153846154,3.0676923076923077,4.061538461538461,5.055384615384615,6.049230769230769,7.043076923076923,8.036923076923078,9.03076923076923,10.024615384615384,11.018461538461539,12.012307692307692,13.006153846153845,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.08,2.073846153846154,3.0676923076923077,4.061538461538461,5.055384615384615,6.049230769230769,7.043076923076923,8.036923076923078,9.03076923076923,10.024615384615384,11.018461538461539,12.012307692307692,13.006153846153845,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.57,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >